Tag: drug development
-
PROGRESS Study Expands Clinical Partnership to Advance Prediction of Radiotherapy Response in Rectal Cancer
Oncosyne is pleased to welcome Haukeland University Hospital as a new clinical partner in the PROGRESS study, joining Akershus University Hospital in investigating whether patient-derived tumoroids can predict radiotherapy response in rectal cancer. The PROGRESS study aims to evaluate whether functional testing of patient-derived tumoroids can help predict how individual patients will respond to radiotherapy…
-
Oncosyne Expands Functional Precision Oncology into Esophageal Cancer
Oncosyne has expanded its functional precision oncology programme into esophageal cancer, with the first patients now recruited and patient-derived tumoroids successfully growing in the laboratory. The milestone is part of the ExPDT study and a collaboration with the surgical team of Dr. Jan Johansson and Dr. Oscar Åkesson at Skåne University Hospital. The study aims…
-
Oncosyne Expands Pancreatic Cancer Patient Cohort to Strengthen Translational Research
Oncosyne has expanded the clinical study within the INVICTA project to include both chemotherapy-naïve and chemotherapy-treated patients with pancreatic cancer. The expanded study broadens the diversity of patient samples available for research and accelerates the growth of a clinically and molecularly annotated biobank of patient-derived pancreatic cancer tumoroids. Developed in collaboration with Sahlgrenska University Hospital…
-
Oncosyne at ESMO Targeted Anticancer Therapies Congress 2026 in Paris 🇫🇷
Oncosyne presented new research at ESMO TAT 2026 showing how patient-derived tumoroid models can support predictive biomarker discovery and strengthen decision-making in early oncology drug development. In the poster, Spatial pharmacoproteomics analysis of patient-derived tumoroids from colorectal cancer to identify predictive biomarkers, the team demonstrated how combining functional drug testing with high-content spatial analysis generates deeper…